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1.1. Anatomy of The Lungs 
 The lungs are a paired organ that can be divided into the left and the right lung. They 
are connected to the trachea via the main bronchi. The entire lung is covered with a serous 
membrane that reduces friction called the visceral pleura, which is continuous with the parietal 
pleura covering the inside of the thorax and surface of the diaphragm. The right lung has three 
lobes: superior, middle and inferior, while the left lung only has two lobes: superior and inferior 
(1). Each lobe is separated from one another by so called fissures. The oblique fissure divides 
the left superior and inferior lobes. The right lung is split into its three lobes by the oblique and 
horizontal fissures. In turn, each lobe can further be divided into multiple bronchopulmonary 
segments. These segments each connect to a segmental bronchus and are supplied with blood 
by separate arteries (2). 
 Air enters the lungs via the tracheobronchial tree. This starts with the trachea, which 
splits into the left and right bronchus. These two main bronchi enter the lung at the hilum. In 
the lung the bronchi again split into the smaller lobar bronchi and eventually the tertiary or 
segmental bronchi. The tracheobronchial tree then further branches into bronchioles and ends 
in the respiratory bronchioles. These in turn give rise to the alveolar ducts, sacs and alveoli, 
with which they make up the functional gas exchanging unit of the lung. These units are called 
acini (2).  
Right and left lung are supplied with blood by the left and right pulmonary artery, 
respectively. A superior and inferior pulmonary vein drain blood from each side. As the 
pulmonary arteries enter the hilum, they become part of the root of the lung and closely follow 
the tracheobronchial tree’s branching pattern. They become lobar and then segmental arteries 
(3). Nutrition and oxygen to the supporting tissues of the lungs, the root of the lungs and the 
visceral pleura is provided by the left and right bronchial arteries. Branches of the bronchial 
arteries reach as far as the respiratory bronchioles. Most the lung’s venous drainage flows into 
the superior and inferior, left and right pulmonary veins, which connect directly to the left 
atrium. The pulmonary veins do not follow the course of the tracheobronchial tree. The 
remainder of the lungs drain into the bronchial veins. These flow into the azygous vein on the 
right and in the superior intercostal or accessory hemi-azygous vein on the right and eventually 
into the superior vena cava and right atrium (2). 
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1.2. Lung Cancer 
1.2.1. Epidemiology and Prevalence 
In 2018 there were a total of 3,021 new cases of lung cancer in Croatia and over two 
million new cases worldwide (4). This makes lung cancer the most common cancer as well as 
the most common cause of cancer deaths worldwide (5-7). While lung cancer incidence is the 
highest in central and eastern Europe and eastern Asia, Croatia has one of the highest incidence 
and mortality rates of all European countries (7,8). Most patients are diagnosed at an advanced 
stage of disease, and despite advances in treatment thanks to decades of research, the prognosis 
remains poor with very low survival rates (5,9,10). Persistent cough, chest pain, hemoptysis 
and weight loss are considered important symptoms of lung cancer, but are fairly unspecific 
(9). All of those are common symptoms of several benign conditions (11). Because stage at 
diagnosis is in correlation with mortality, this explains lung cancer`s extraordinary mortality 
rates, which are higher than for any other cancer. Almost every fifth patient that dies of cancer 
in the world had lung cancer (7). 
The incidence and mortality of lung cancer vary with age, sex, ethnicity and 
socioeconomic groups. Advanced age is associated with cancer and decreased survival rates in 
both sexes (10). The average age at diagnosis is around 70 years and older (5,10). There are 
differences especially in incidence between the sexes. Men have significantly higher overall 
incidence rates than women (7). Worldwide, lung cancer is the most common oncologic 
condition in men, though ranking second in more developed countries after prostate cancer. 
For women lung cancer`s incidence is second only to breast cancer, while having one of the 
highest mortality rates (7,12). In 2013, lung cancer was the third most common cancer of 
women in Croatia and came 4th  in 2018, while men were only diagnosed more often with 
prostate cancer (4,8). In more developed countries one can find increased rates of lung cancer 
as well as increased mortality (5,10). This can be explained by higher rates of smokers and a 
longer history of smoking in those countries. 
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1.2.2. Etiology 
There is no doubt today that the most important risk factor and causative agent for lung 
cancer is cigarette smoking (5,8,12). The incidence of cancer has continuously risen since the 
1930s when smoking became popular and it closely follows smoking prevalence (8,12). Even 
though there has not been any major breakthrough as with other malignancies, lung cancer has 
recently seen a decline in mortality. This is thanks to a continuous reduction in smokers and 
progress in early detection and treatment (6,10). In the period 2001 to 2013, data suggests that 
every fourth adult Croatian was an everyday smoker, which is of immense clinical importance, 
considering that smoking accounts for almost 90% of lung cancers (5,8). 
It is known since the 1950s that there is a correlation between smoking and lung cancer. 
Since then scientists have identified a wide variety of carcinogens in cigarette smoke 
(10,13,14). This direct correlation between tobacco smoking and the development of lung 
cancer creates a unique potential for risk reduction. Today many countries have introduced 
anti-smoking campaigns and banned advertising in an effort to reduce the number of smokers 
(12). However, globally the total number is expected to increase to 1.9 billion by 2025, if the 
current trend does not change, making it a worldwide health crisis even though just 1 in 9 of 
those will eventually get lung cancer (10). 
The amount of carcinogens and tar inhaled varies between cigarette brands, the 
presence and effectiveness of a filter, the duration and intensity of inhalation and how long the 
smoke was allowed to cool before inhalation (10). NNK (4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone) and PAH (polycyclic aromatic hydrocarbon) are two of the carcinogens contained 
in tobacco smoke (14). NNK is considered the most important inducer of cancer by causing K-
ras oncogene activation, found in 24% of lung adenocarcinomas, while PAH causes mutations 
in the p53 tumor suppressor gene found in about 40-60% of primary lung cancers and neither 
of these mutations necessarily disappear with smoking cessation (10,13). The same carcinogens 
are inhaled by passive smokers, however at much lower doses (13). 
Approximately a quarter of all lung cancer patients worldwide are "never smokers". 
"Never smokers" are defined as having smoked fewer than 100 cigarettes in their lifetime. 
These 25% of patients are mostly women and younger patients, and have a better survival rate 
than smokers (5,10). 
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In addition to smoking there are other risk factors for lung cancer, which can be 
behavioral, environmental and genetic (5). They include, but are not limited to air pollution, 
occupational exposure to chemicals and carcinogens such as asbestos, silica dust and arsenic, 
infections, COPD and residential exposure to radon. Radon is the second most common risk 
factor after smoking, generating about 10% of cases. Asbestos is the most common 
occupational carcinogen, which as a group accounts for approximately 5-10% of lung cancers. 
How likely an induvial is to develop lung cancer in part also depends on his or her genetic 
susceptibility (5). Furthermore, the risk of lung cancer increases multifold with a first-degree 
relative who previously developed the disease (5,8,10). This is why a positive family history 
of lung cancer can be an indication for cancer screening (15).  
 
1.2.3. Histology/Classification 
The progression from normal cells, through preneoplastic and eventually into malignant 
cells involves a series of changes in DNA (10). This process starts with metaplasia of the 
bronchial epithelium and is initially reversible. With repeated exposure to irritants and 
carcinogens eventually neoplastic cells with uncontrolled proliferation develop, which at this 
stage is called carcinoma in situ (16). At this stage, the cancer is still contained and 
asymptomatic. With more extensive spread and local tissue invasion, the tumor can cause 
obstruction, nerve damage and plural effusion (16). These can manifest as cough, pain, 
hemoptysis and difficulty breathing.  
For simplicity, lung tumors are divided into small-cell lung carcinomas (SCLC) and 
non-small-cell lung carcinomas (NSCLC) (16). NSCLC make up for 85% of lung cancers and 
includes adenocarcinomas, squamous cell carcinomas and large cell carcinomas. Out of these, 
adenocarcinoma has recently become the most common subtype (10,14,17). Tumors arise more 
often in the right lung and in the upper lobes (17). 
 
1.2.3.1. Small-Cell Lung Carcinoma 
 SCLC arise from neuroendocrine cells and bare the worst prognosis of the different 
lung cancer types (16). Small-cell lung carcinoma has two stages. If it is contained to one 
hemithorax it is called limited. If it has spread beyond a single hemithorax it is referred to as 
extensive stage (18). SCLCs are most often found centrally in the lung and metastasize early 
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(19). Metastasis can be found in many places, but most commonly in the ipsilateral pulmonary 
and hilar lymph nodes, mediastinal lymph nodes, the rest of the lung, liver, bone and even brain 
(17). 
 
1.2.3.2. Non-Small-Cell Lung Cancer 
 Generally, NSCLC have a better prognosis as well as 5-year survival rate. Non-small 
cell lung carcinoma can be staged using the TNM system, which is based on the tumor (T), 
lymph node status (N) and presence/absence of metastases (M), as seen in Table 1. In addition 
it can be categorized into early cancer without mediastinal involvement (I/II), locally advanced 
cancer (III A/B) and metastatic cancer (IV) (17,18). The most common type of NSCLC, the 
adenocarcinoma, is typically a peripheral tumor (10,17). 
Table 1. TNM Staging of Lung Cancer (20) 
Tumor  
Tx Tumor cell in sputum/bronchial washing but not assessed in imaging or bronchoscopy 
T0 No evidence of tumor 
Tis Carcinoma in situ 
T1 ≤ 3cm surrounded by lung/visceral pleura, not involving main bronchus 
  T1a(mi) Minimally invasive carcinoma 
  T1a ≤ 1cm 
  T1b > 1 to ≤ 2 cm 
  T1c > 2 to ≤ 3cm 
T2 > 3 to ≤ 5 cm or involvement of main bronchus without carina, regardless of distance from 
carina 
  T2a > 3 to ≤ 4 cm 
  T2b > 4 to ≤ 5 cm 
T3 > 5 to ≤ 7 cm in greatest dimension or tumor of any size that involves chest wall, 
pericardium, phrenic nerve or satellite nodules in same lobe 
T4 > 7 cm in greatest dimension or tumor with invasion of mediastinum, diaphragm, heart, 
great vessels, recurrent laryngeal nerve, carina, trachea, esophagus, spine or separate tumor 
in different lobe of ipsilateral lung 
Nodes  
N1 Ipsilateral peribronchial and/or hilar nodes and intrapulmonary nodes 
N2 Ipsilateral mediastinal and/or subcarinal nodes 
N3 Contralateral mediastinal or hilar; ipsilateral/contralateral scalene/supraclavicular nodes 
 
 
Metastasis 
 
M1 Distant metastasis 
  M1a Tumor in contralateral lung or pleural/pericardial nodule/malignant effusion 
  M1b Single extrathoracic metastasis, including single non-regional lymph node 
  M1c Multiple extrathoracic metastasis in one or more organs 
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1.3. Treatment Options of Lung Cancer 
Lung cancer can generally be treated with radiotherapy, chemotherapy, surgery or a 
combination of these treatment modalities (17,18). However, small-cell lung carcinoma is 
widely considered inoperable due to its tendency to metastasize early and its characteristically 
difficult to operate tumors. Exact treatment plans are tailored to each patient based on the 
specific tumor and its stage, as well as the physical and mental state of the patient.  
 
1.3.1. Radiotherapy 
 The use of radiotherapy in oncology is very versatile. If for any reason surgery is 
contraindicated for a patient with stage I/II NSCLC, radiotherapy is a good alternative. This 
also includes patients that refuse to undergo surgery. For early stage disease, radiotherapy can 
even be curative and at locally advanced stages radiotherapy often becomes the treatment of 
choice (17,21,22). In addition, radiotherapy can be used postoperatively and even 
preoperatively to improve survival (17,22). A good example for this are Pancoast tumors, also 
called superior sulcus tumors. Pancoast tumors are a group of tumors that penetrate the apical 
chest wall. They produce a special set of symptoms consisting of severe pain in the arm and 
shoulder, atrophy and weakening of hand muscles, Horner`s syndrome and edema (23). This 
results out of the tumors proximity to anatomic structures like the brachial plexus, phrenic and 
vagus nerves, sympathetic ganglia and major blood vessels. The main treatment modality 
consists of perioperative chemoradiation (24). 
 Even though small-cell lung carcinoma is primarily treated with chemotherapy, there 
have been studies that show improved survival for limited stage disease with the use of 
concomitant radio- and chemotherapy. For advanced stages however, regardless of NSCLC or 
SCLC, radiotherapy is only of palliative value (16,17). 
Radiation damages surrounding tissues and can have severe adverse effects, hence it is 
important to always weigh its benefits against potential downsides (22). Standard protocols for 
the radiologic treatment of lung cancer vary between countries and institutions and proper 
radiologic treatment involves meticulous planning for each individual patient.  
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1.3.2. Chemotherapy 
 Chemotherapy is especially of value for the treatment of small-cell lung carcinoma and 
for patients with metastatic disease. It is the mainstay of treatment for limited SCLC, but 
research also indicates that adjuvant chemotherapy can be of benefit in early stage NSCLC. If 
NSCLC is locally advanced and inoperable, it is best treated with a concomitant combination-
agent chemotherapy and radiation (17). Exact treatment protocols vary and are tailored to the 
specific tumor. One well established and common treatment regimen is a cisplatin-based 
adjuvant therapy. Platinum-based chemotherapy to improve survival and quality of life in 
advanced NSCLC is another example (25). Just like radiotherapy, chemotherapy can have 
severe systemic toxicity. Therefore, it needs to be administered with extreme care and its value 
to the patient at his or her specific stage of disease needs to be thoroughly considered. A recent 
development has been to treat inoperable stage III NSCLC with targeted immunotherapy, such 
as the monoclonal antibody durvalumab or the EGFR inhibitor afatinib (26,27) 
 
1.3.3. Surgery  
 Surgery is the fundamental treatment modality for early stage non-small cell lung 
cancer and can even improve the outcome in very localized small-cell lung carcinomas (17,21). 
As mentioned above, surgery can also be performed with neoadjuvant and /or adjuvant chemo- 
or radiotherapy. How radical the surgical resection needs to be performed depends on the stage 
and location of the primary tumor, and generally anatomical resections with systematic nodal 
resections are performed (17). Surrounding lymph nodes, most commonly mediastinal and/or 
hilar, are resected to check for metastasis. Regardless of the type and extent of operation, the 
completeness of resection, oncologic efficacy, safety and survival are the most important points 
to consider (28-30). Different surgical approaches will be discussed below. 
 
Principally surgery requires a patient in good health, who is fit enough to undergo the 
stress of anesthesia and a lengthy recovery process. This is determined by age, cardiovascular 
and pulmonary function tests, comorbidities, performance status and nutrition (17,31). 
Especially important is the patient`s pulmonary reserve as it limits the possible extent of the 
resection (32,33).  
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Surgery is indicated for stage I/II NSCLC, with lobectomy being the standard of care. 
It can also be applicable in conjunction with chemo- and radiotherapy for larger, locally 
advanced NSCLC without metastasis (31). Small-cell lung cancer is typically considered 
inoperable due to its tendency for early metastasis and special morphology of tumors. However, 
resection of small peripheral small-cell lung tumors can improve the patient`s survival rate 
(17,31).  
 
1.4. Thoracotomy 
 For a long time, if surgery was indicated, thoracotomy was the treatment of choice for 
lung cancer patients (28,34). Despite advances in thoracoscopic procedures, which are now the 
treatment of choice, posterolateral and anterolateral thoracotomies are still being performed 
(34,35). They are still indicated for large or difficult to reach tumors, where the posterolateral 
open approach enables improved exposure compared to minimally invasive techniques (36).  
 There are two commonly used versions of the open technique: classical posterolateral 
thoracotomy and muscle-sparing posterolateral thoracotomy (37). The innovation of the 
muscle sparing technique has been of great clinical value, as the separation of large muscles 
was one of the classical procedure`s biggest disadvantages (36). The patient is placed in a 
lateral decubitus position to achieve maximum spreading of the intercostal spaces and then a 
cut through skin and subcutaneous tissue is performed just beneath the tip of the scapula. The 
incision closely follows the contour of the rib, which should be around the 6th rib (37). Once 
the latissimus dorsi and serratus anterior muscles are reached, the two operations differ in either 
transecting the muscles (classical) or separating their respective attachments and thereby 
sparing the muscle fibers themselves (muscle-sparing) (36). Next, the muscles in the chosen 
intercostal space are divided along the superior border of the lower rib, in order to avoid neve 
and vascular damage, which is a common postoperative complication in thoracotomies (35,37).  
Then, after rib retraction, the pleural space can be entered, and the necessary resection 
performed. After a drainage is placed, the incision is closed stepwise in order to achieve the 
best healing outcome, starting with pericostal sutures. These are followed by subcutaneous and 
skin sutures. Finally the chest drains is fixed to the skin (37). 
 When thoracoscopic operations are performed, there may be complications like major 
bleeding, incomplete lung collapse, dense adhesions and other unforeseen technical, 
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anatomical and oncological issues. In those cases, it may be necessary to convert the operation 
to an open thoracotomy (38-40). This is achieved by either connecting multiple ports, if present, 
or enlarging the single incision in case of a uniportal approach. However, unplanned conversion 
bare higher risks of morbidity, mortality and cancer recurrence and should therefore be avoided 
if possible (38,41). 
An open thoracotomy is a major surgery and bares general surgical risks connected to 
general anesthesia, bleeding and infection. In addition, there are some well-established 
disadvantages of an open thoracotomy specifically. As mentioned above one of the most 
common problems of the non-muscle-sparing technique is a postoperative limitation in muscle 
movements of the chest and shoulder girdle (36). It limits early mobilization and requires 
extensive physical therapy. Another complication is severe postoperative pain. A large portion 
of patients suffer of chronic pain syndromes and require analgesic treatment for months or 
years. This results out of damage to intercostal nerve fibers during spreading of the and/or 
incision in the intercostal space. In some cases, a rib may even be fractured in this process (37).  
 
1.5. Thoracoscopy 
The first thoracoscope was invented by Jacobaeus, a Swedish doctor, at the beginning 
of the 20th century and since the 90s multiportal VATS has firmly established itself in the world 
of thoracic surgery (29,39). This minimally invasive approach to lung surgery has many 
advantages, also seen in other fields that apply keyhole surgery. Those include: smaller 
incisions and therefore better cosmetic results, less postoperative pain, reduced blood loss, 
faster recovery and thereby hospital stay, and decreased morbidities and mortality (39,42,43). 
Modern thoracoscopic procedures can be categorized by the specific surgical approach, into 
multiportal and uniportal VATS. 
 
1.5.1. Multiportal VATS 
VATS stands for video-assisted thoracic surgery and multiportal refers to the number 
of incisions used by the surgeon. After it was proven that multiportal VATS  lobectomy had an 
equivalent oncological efficacy for lung cancer as open thoracotomy and was a safe procedure, 
it quickly became the new gold standard of care for lung cancer in many institutions (28,34,44).  
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 VATS is performed under general anesthesia with the patient being in a lateral 
decubitus position just like in the open procedure. Usually double-lumen intubation is used in 
order to facilitate the ventilation of only one side of the lung (45). The exact number of ports 
or trocars vary but most common are triportal or biportal approaches that require incisions of 
3-5 cm (29,41,46). Once the pleural space is entered, the steps are almost identical to resection 
via thoracotomy (43). At the University Hospital of Split most multiportal VATS are performed 
utilizing only two ports. One for the operative tools and one utility port for the thoracoscope 
and later drain placement.   
Contraindications for video-assisted thoracic surgery are very large tumors that cannot 
be evacuated through the small incisions and such tumors that are too locally invasive or 
advanced in order to be sufficiently resected via this approach (38,47). 
 
1.5.2. Uniportal VATS 
1.5.2.1. Definition 
Uniportal refers to the amount of ports or openings used during the operation. Therefore 
"Uniportal VATS" describes a minimal invasive, laparoscopic surgical technique that utilizes 
one single, small incision in the chest wall (29,45).  
 
1.5.2.2. History 
Multiportal VATS has existed for decades in the world of thoracic surgery and has 
proven to be advantageous in many ways, as discussed above. Since then, surgeons have 
continuously thrived to further reduce the invasiveness of operations in the hope to increase 
postoperative quality of life, without compromising safety and oncological efficacy (46,48).  
This ultimately led to the introduction of uniportal VATS, which was first depicted by Rocco 
and colleagues (45). At first, the uniportal approach was utilized mainly for minor thoracic 
procedures like treatment of pneumothorax, biopsies, wedge resections and evacuation of 
hemothorax (39). There were doubts about uniportal VATS being suitable for more 
complicated procedures in regard to its safety and oncologic results (41,49,50). However, 
multiple studies in recent years have eliminated these doubts to the most extent and proven that 
the uniportal approach is safe, and at least equivalent to the gold standard (29,51,52). 
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The evolution of uniportal VATS mainly became possible due to the development of 
better video cameras, improved energy devices and specialized surgical equipment such as 
articulated endoscopic staplers and curved, thinner instruments (29,49,53). The pinnacle of this 
progress was in 2010, when Gonzalez-Rivas executed the first uniportal lobectomy for early 
stage lung cancer (29,42). Since this milestone the uniportal technique has become widely used 
for major, more complicated surgeries such as lobectomies, vascular reconstruction and sleeve 
lobectomies (29,39,42,54).  
 
1.5.2.3. Procedure 
Uniportal VATS is performed under general anesthesia with double-lumen intubation 
(40,44). The patient is placed in a lateral decubitus position just like in the open and multiportal 
techniques (44,45). A single incision of 4-6 cm is made in the 4th to 6th intercostal space, either 
in the mid-axillary line or the anterior chest wall. The location of the incision largely depends 
on the position of the pulmonary lesion (44,53). The leading surgeon and his assistant both 
stand in front of the patient, as seen in Figure 1 (42).  
 
Figure 1. Position of Surgeons and Patient (55) 
Dr. Beth Croce, Medical Illustrator for the Annals of Cardiothoracic Surgery 
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Most often, a 30-degree thoracoscope is used (34,53). The single access is used for 
camera entry, surgical instruments as well as specimen retrieval at the end of the operation 
(48,51). The idea is to create conditions similar to the open technique, only with the operative 
fulcrum moved into the chest cavity (40). This creates a parallel orientation of instruments and 
the thoracoscope, which facilitates improved eye-to-hand coordination and preserves depth of 
the visual field (41,48). To provide the best overview of the operating field the camera is kept 
most of the time in the posterior (upper) edge of the incision (55). 
The exact sequence of the operation differs with the type of resection and anatomical 
variation. A commonly applied order is to first dissect the pulmonary vein, then the artery and 
at last the main bronchus (44,45). To perform a left lower lobectomy, the lung is retracted, and 
the pulmonary ligament is exposed. The ligament is then cut open in order to reveal the 
pulmonary vein. Next the pulmonary artery and then the bronchus are divided. The resection 
is completed by division of the fissure (55). Fissure and blood vessels are divided by staplers 
if possible. Sometimes the angle is too awkward to use a stapler, in which case vascular clips 
or sutures may be used. Once resected, the lobe is removed in a protective bag.  
For a right lower lobectomy, the steps are essentially the same as for the left side. However, 
special attention must be directed to identifying and avoiding the bronchus and artery of the 
middle lobe. This may require the removal of inter-bronchial lymph nodes before dividing the 
artery.  
To perform a left upper lobectomy, it is recommended to initially divide the upper 
arterial trunk. After that step, the upper lobe vein is divided (47). At last the bronchus and 
fissure are stapled. In order to achieve a right upper lobectomy similar steps are followed. As 
with lower right lobectomy, middle lobe structures must be identified and protected before the 
fissure is divided. The middle lobe is resected by first cutting the anterior part of the major 
fissure. This exposes the vein and enables its dissection. Next, the bronchus is revealed and 
stapled. Finally, the medial segmental artery and then the remaining of portion of the fissure 
are divided (45). 
After resection of the lung is accomplished and the specimen is removed in an endobag 
to avoid tumor seeding and spillage of tumor contents (48,53,55). Then surgeon carries out a 
systematic lymph node dissection (53). In order to remove subcarinal, paratracheal and hilar 
lymph nodes, the operating table is moved into different positions. This moves the lung and 
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provides better angles for resection (45). Once completed, the incision is closed by suturing the 
muscles and subcutaneous tissue, without applying intercostal sutures, and a chest drain is 
placed (47,53).  
 
1.5.2.4. Indications and Advantages 
 Uniportal VATS has similar prerequisites as multiportal VATS in regard to patient 
selection, and the same preoperative check-ups as for any surgical patient should be carried out 
(55). In addition, research suggests that the uniportal technique may be more suitable for 
elderly patients and patients with poor pulmonary reserve (41). 
 When uniportal VATS first entered the field of thoracic surgery, possible advantages 
included decreased postoperative pain, shorter hospital stays and earlier mobilization (39,53). 
However, many studies have shown that there is no difference between uniportal and 
multiportal treatment outcomes except in regards of pain control (49,56). Still, these studies 
also show as mentioned previously, that uniportal VATS is safe and has comparable 
oncological results.  
Uniportal VATS has some benefits over its multiportal counterpart, nonetheless. It 
provides a more direct view of the structures of interest and anatomy inside the chest (51). In 
addition, the parallel orientation of instruments and thoracoscope technically make the 
operation easier and prevents awkward angles that are intrinsic to the multiportal technique 
(44). 
 
1.5.2.5. Contraindications and Limitations 
 Contraindications are mostly concerned with tumor size as well as competency and 
comfort of the surgeon (45,47). If the tumor is too large to be retrieved through the single 
incision or too difficult to reach, the uniportal technique may not be applicable. Furthermore, 
the small single incision can become crowded by the camera and several surgical instruments, 
which may be interfering with each other inside the pleural space (49). This however can be 
limited with long, thin and angulated specialized instruments (45). Some medical institutions 
also mention the issue of not being able to palpate and identify small lesions through the 
incision (44,47). Uniportal VATS requires a lot of experience and training. It's learning curve 
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is strongly influenced by the number of performed surgeries and previous experience with 
minimally invasive techniques (52). 
 As with any operation there are risks connected to infection and anesthesia. The limited 
space in the uniportal technique can make it difficult to control bleeding. Additionally, 
prolonged air leak may result out of an improper resection of a bronchus. Major bleeding, 
technical difficulties or anatomical variations may make a conversion to an open operation 
necessary (39).  
 
1.5.2.6. Further Developments 
 In 2014, Liu et al. performed the first successful left upper lobectomy through a 
subxiphoid incision. The subxiphoid approach is a variation of uniportal VATS. It utilizes a 
single incision just below the sternum, as the name suggests. The location of the incision has 
the advantage that it is not limited by the intercostal spaces. That means that intercostal nerve 
damage can completely be avoided and simplifies specimen retrieval. In addition, the 
subxiphoid approach provides an improved view on hilar structures and produces better 
cosmetic results.  
On the other hand, it has been noted that major bleeding may be difficult to control and special 
instruments, as well as surgical training are required to ensure safety and efficacy (39,41). 
 Another recent advance in thoracic surgery has been to perform surgery on an awake, 
non-intubated patient (42). An epidural catheter, paravertebral and vagal nerve blocks achieve 
the required anesthesia. This technique was originally developed to avoid postoperative 
complications associated with intubation such as airway injuries, ventilation-related injuries, 
nausea, vomiting and pneumonia. It requires a very competent anesthesiologist, capable of 
immediate conversion to intubated general anesthesia and the surgeon must have a clear 
conversion plan in case of any complications. Extensive previous experience with minimally 
invasive surgery is of utmost importance. In addition, patients must be carefully selected. 
Obesity, coagulation disorders, non-compliance for awake surgery, ASA score above two and 
hemodynamic instability are all contraindications for the non-intubated approach (39). 
 
 
  
2. OBJECTIVES
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AIMS: 
1. Determine the surgical duration, duration of chest drainage, and length of postoperative 
period for the 3 different surgical techniques. 
2. Compare the parameters among the 3 techniques to find differences and possible 
superiorities. 
 
HYPOTHESIS: 
Uniportal VATS is a superior procedure (measured by surgical duration, duration of chest 
drainage, and length of postoperative period) compared to multiportal VATS and open 
thoracotomy for the treatment of lung cancer.  
 
 3. SUBJECTS AND METHODS
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3.1. Data Collection 
Patient data was obtained from the archives of the Department of Surgery, University 
Hospital of Split. Data collected was the age, name and gender of each patient, his or her 
diagnosis, the dates of admission, release and operation, the type and length of operation and 
duration of chest drainage.  
 
3.2. Subjects 
 Any patient that was surgically treated for lung cancer at University Hospital Split in 
the years 2016, 2017 and 2018 was included in the original data sampling. The first operation 
recorded was on the 7th of January 2016 and the last on the 15th of November 2018. In some 
instances, it was not possible to cross-reference a release document with the corresponding 
patient file and those patients were excluded due to insufficient data. Patients that didn’t 
undergo either uniportal VATS, multiportal VATS or open thoracotomy were excluded as well. 
After exclusion there was a total of 150 patients included in the retrospective study. 
 
3.3. Description of the Study 
The subjects were grouped into five study groups according to the type of operation 
they underwent. The three main groups: Open Thoracotomy, Multiportal VATS, Uniportal 
VATS and two subgroups in which operations had to be converted to an open procedure: 
Converted Multiportal VATS and Converted Uniportal VATS. In the three main study groups 
there were 114 patients, while the two conversion groups included 36 patients in total. In order 
to evaluate the different types of operations and compare the three main study groups, three 
parameters were calculated and defined as primary outcomes measures of the study.  
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3.3.1. Primary Outcomes 
 The primary outcomes of this retrospective study were: 
• The duration of the operation obtained from the surgical protocol, measured in 
minutes 
• The recovery time, which is the difference of the date of operation and the date 
of release, measured in days 
• The duration of chest drainage, starting from the day of operation until the day 
the drain was removed, measured in days 
 
3.3.2. Secondary Outcomes 
 Secondary outcomes were the age and gender of each patients as well as the conversion 
rates of uniportal and multiportal VATS operations, respectively. 
 
3.4. Statistical Analysis 
 Statistical analyses were performed using statistical software MedCalc for Windows, 
version 19.0.4 (MedCalc Software, Ostend, Belgium). Continuous data was expressed as 
medians with 95% confidence intervals, while categorical data was presented as whole 
numbers and percentages. 
 Chi-square tests were performed for gender and conversion ratio comparisons, with a 
P value <0.05 being statistically significant. Age, operation duration, recovery time and 
drainage duration were all compared among the different study groups using the Kruskall 
Wallis test, also with a P value <0.05 being statistically significant.  
 
  
4. RESULTS
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 A total of 150 patients were included in the study. Patient ages ranged from 18 to 79 
years. From total number of patients, 94 were male (62.67%) and 56 patients female (37.33%). 
Table 2 shows the age and gender distribution among the main study groups. There was no 
statistically significant difference in age and gender between them. The median age of patients 
in all three groups was above 60 years.  
Table 2. Gender and Age Distribution 
(N=114) 
Multiportal 
VATS 
(N=59) 
Uniportal 
VATS 
(N=32) 
Open 
Thoracotomy 
(N=23) 
P 
Female gender 
(n, %) 
23 (39) 17 (53.1) 5 (21.7) 0.287* 
Age (years) 63(59.5-65.0) 
64.5 (61.9-
67.0) 
64 (57.3-69.0) 0.569† 
Data are presented as median (95% CI) or as absolute number (%) 
* Chi Square test 
† Kruskall Wallis test 
 
The operation parameters for the investigated 3-year period are summarized in Table 3. 
When an operation is first attempted in a minimally invasive fashion and then must be 
converted for any reason, it inherently becomes a longer intervention and is often followed by 
a prolonged recovery period. Therefore, the study only compares operation parameters among 
the three main groups which maintained their respective operation method without being 
converted. 
Table 3. Operation Parameters 
(N=114) 
Multiportal 
VATS 
(N=59) 
Uniportal 
VATS 
(N=32) 
Open 
Thoracotomy 
(N=23) 
P* 
Operation 
duration (min) 
150 (120.0-
180.0) 
110 (70.0-
150.0) 
145 (120.0-
180.4) 
0.093 
Recovery time 
(days) 
7 (7.0-7.0) 7 (6.0-8.0) 9 (7.0-11.0) 0.086 
Drainage 
duration (days) 
5 (4.0-5.0) 5 (4.0-5.0) 6† (5.0-7.0) 0.016 
Data are presented as medians (95% CI) 
* Kruskall Wallis test 
† Significantly different than other two groups. 
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All operations assessed in Table 3 were major lung resections such as pneumectomies, 
lobectomies and sub-lobar resections. Over the last 3 years, most patients were operated by 
multiportal VATS (N=59). This was followed by uniportal VATS with 32 patients. Only 23 
patients were originally operated by open thoracotomy.  
Operation duration, recovery period and drainage duration were determined as good 
outcome measures in order to assess a potential superiority of one of the procedures, 
particularly uniportal VATS. Statistical analysis using the Kruskall Wallis test showed that 
there was only a statistically significant difference in drainage duration (P=0.016), with open 
thoracotomy having a significantly longer chest drainage time than the other two operation 
methods. 
Table 4 presents, how many multiportal and uniportal VATS procedures had to be 
converted for any reason. The Chi-square test was performed and showed no statistically 
significant difference in conversion rates between the two operations.  
Table 4. Conversion to Open Thoracotomy 
 Multiportal VATS Uniportal VATS P* 
Total 87 40  
Converted 28 8  
Conversion Ratio 0.32 0.20 0.283 
*Chi-square 
 
 Uniportal VATS has only been performed for a few years at the University Hospital of 
Split. The obtained data was therefore additionally examined for each individual study year in 
order to see whether there was a learning curve manifesting itself by a decline in uniportal 
VATS operation duration over time. However, there was no clear trend to be seen. Although 
this was in part due to missing data sets, which made the construction of a graph impossible.  
 
 
 
  
5. DISCUSSION
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 Uniportal VATS has been routinely performed in the last few years for the treatment of 
lung cancer at the University Hospital of Split. At the same time, open thoracotomies and 
multiportal VATS have been continuous treatment modalities for lung cancer. In this 
retrospective study we examined whether uniportal VATS can be considered a superior surgery 
compared to multiportal VATS and thoracotomy. In order to compare the different procedures, 
outcome measures that reflect efficiency of the operations and postoperative quality of life had 
to be defined. In our study these parameters were limited to the duration of the surgery itself, 
the recovery period defined as the time between the operation and the release from the hospital, 
and the duration of the thoracic drainage.  
 Following the rising popularity of uniportal VATS in recent years there have been many 
studies comparing it to the current choice of treatment, multiportal VATS, and open 
thoracotomy. At first, uniportal VATS had to prove its safety for the patient in order to even 
be considered as an alternative. Additionally, when used for the treatment of lung cancer, the 
oncological efficacy of uniportal VATS is of utmost importance (29). Safety of a procedure is 
typically assessed by mortality and conversion rates. In our study there was no significant 
difference in the conversion rates of uniportal and multiportal VATS suggesting a comparable 
risk and safety of the two procedures. This finding is in concordance with research done in 
Germany and Taiwan (42,48). Furthermore, other studies have found similar mortality and 
morbidity between the minimally invasive operations, while being significantly lower 
compared to open thoracotomy (39). Oncologic efficacy can be measured in two ways: the 
number of lymph nodes and lymph nodes stations during resection and long-term survival and 
recurrence rates (30). Despite doubts it has now been demonstrated in multiple studies that 
comparable standards of resection between uniportal and multiportal VATS as well as open 
thoracotomy are possible (28). 
 After establishing uniportal VATS safety and oncologically equivalence, it makes sense 
to look at potential benefits compared to the gold standard treatment. Uniportal VATS utilizes 
only a single incision which, compared to the multiportal or open surgery, produces much less 
trauma. Probably the most commonly suggested advantage of uniportal VATS has been 
reduced postoperative pain as a direct result of its reduced invasiveness (53). Other proposed 
benefits are a shorter hospital stay, leading to reduced costs and a shortened recovery period 
(39). In our study we did not investigate the postoperative pain of patients. This is because it 
requires data collected in the form of a pain scoring system like the analog pain scale for each 
patient.  
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Not only is this data a subjective measurement, but it is also not routinely collected at the 
University Hospital of Split and therefore impossible to gather in a retrospective manner. 
However, multiple studies have found lower postoperative pain scores and pain for uniportal 
VATS (29,39,44). 
 In our study we assessed the postoperative outcome by measuring the length of the 
immediate recovery period. This was defined as starting after the surgery and ending with the 
release of the patient from the hospital. A less invasive surgery should lead to a quicker 
recovery. Furthermore, if there were and intra-or postoperative complications, they should be 
reflected in a prolonged hospital stay. Despite this assumption, we did not observe any 
statistical difference in recovery time between uniportal VATS, multiportal VATS and open 
thoracotomy. These results have been reproduced in other studies and suggest the need for 
further investigations of the actual impact of the type of surgery on the duration of the recovery 
period following lung cancer (44,51). Another postoperative outcome we investigated was how 
long a chest drainage was necessary. As mentioned previously, prolonged air leakage may be 
a complication of lung surgery. Therefore, we selected chest drain duration as an easy to assess 
surrogate for general postoperative complications and intraoperative precision. Results showed 
that patients operated for lung cancer with an open thoracotomy required a chest drain for 
significantly longer time than uniportal and multiportal VATS techniques. They also showed 
that there was no statistical difference in drainage time between the two minimally invasive 
groups.  
Other studies have demonstrated mixed results regarding chest drainage. Some have 
found that there is no difference between surgical techniques whatsoever, while others suggest 
that the drainage duration is reduced with uniportal VATS (44,48,56). It seems possible that 
the extent of the lung resection, comorbidities and other factors related to pulmonary function 
and anesthesia affect the exact results. Therefore, we would suggest that in further studies a 
more standardized approach should be taken in order to decrease possible variables as much as 
possible. 
 The third parameter we investigated in our study was the operation duration. This was 
obtained from the surgery documentation forms of each patient. How long an operation takes 
on average can give a good indication on how readily it can be performed and how complex it 
is. Furthermore, if looked at over a period of time, it can project a learning curve of the surgeon.  
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In our study operation times did not significantly differ between the three investigated 
operations throughout the last three years. Again, these results confirmed the findings of other 
studies (44,48).Operations that had to be converted had very long durations. This, however, is 
to be expected as a minimally invasive attempt followed by a conversion and after that an open 
procedure, naturally requires more time. Therefore, we excluded converted operations from the 
comparisons.  
 Since the overall patient data was incomplete with regard to the operation time and - as 
far as recorded, the operation durations did not show a decreasing trend over the investigated 
3-year period, we were not in a position to comment on a learning curve regarding VATS. 
 Overall, our analysis confirms the trend of other studies that compare uniportal VATS 
with other treatment modalities for the treatment of lung cancer. Uniportal VATS is safe and 
although not investigated by us, seems to provide equivalent oncologically results as 
multiportal VATS and open thoracotomy (28,29). Generally, uniportal VATS can reach 
equivalent outcomes to its multiportal counterpart and both minimally invasive techniques 
appear to be superior to open thoracotomy in certain aspects. In order to say whether or not 
uniportal VATS is superior to multiportal VATS for the treatment of lung cancer, however, 
requires further research and especially long-term studies. Most patients in Split have been 
operated for lung cancer by multiportal VATS, which is the current international treatment of 
choice. At this stage though, uniportal VATS can be a viable alternative and its utilization 
probably depends on the surgeon's preference.  
 Our study has several limitations. First, we did not take the tumor staging of each patient 
into account. The size and invasiveness of a tumor can have great effects on the course of an 
operation. Even though most patients included in the study underwent a lobectomy, other types 
of resections were included which might have further limited the validity of parameters like 
operation time and drainage duration. Second, the surgeries included were carried out by 
different surgeons. This makes it harder to compare them, as each individual surgeon might be 
more comfortable with a different operation modality and therefore affect the outcome 
measures.  
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 In order to determine the future role of uniportal VATS for lung cancer treatment at the 
University Hospital of Split and other medical centers, more investigations are needed. They 
should include additional parameters like postoperative pain scores, intraoperative blood loss, 
cancer recurrence and long and short-term survival rates. The data collection should be 
performed in a prospective manner. This would make it possible to follow the patients 
throughout the treatment process as well as ensure that all variables of interest are being 
recorded. Moreover, more significant results could be obtained if patients are divided by their 
tumor stage and operations are grouped according to the extent of resection.  
 
  
6. CONCLUSIONS
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1. Open thoracotomy patients had a significantly longer duration of chest drainage than patients 
that underwent uniportal VATS or multiportal VATS operations.  
2. There was no significant difference in the duration of chest drainage between uniportal 
VATS and multiportal VATS 
2. There was no significant difference in the recovery time of patients undergoing open 
thoracotomy, uniportal VATS or multiportal VATS. 
4. There was no significant difference in the operation duration between open thoracotomy, 
uniportal VATS or multiportal VATS. 
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Objectives: The aim of this study was to determine the operation duration, chest drainage 
duration and length of postoperative hospital stay for lung cancer patients that underwent either 
uniportal VATS, multiportal VATS or open thoracotomy surgeries at the University Hospital 
of Split in the observed period. Furthermore, the study compared the three operation 
techniques, using the determined parameters, in order to investigate possible superiorities or 
inferiorities between them. 
 
Subjects and Methods: From January 2016 until December 2018, 150 patients (94 males and 
56 females) who underwent surgery for the treatment of lung cancer at the Department of 
Surgery, University Hospital of Split, were included in the retrospective study. Patients were 
divided according to the type of surgery they underwent. There were three main groups: 
Multiportal VATS (N=59), Uniportal VATS (N=32) and Open Thoracotomy (N=23). These 
groups were compared regarding operation duration, chest drainage duration and length of 
postoperative hospital stay. In addition, two subgroups for converted uniportal and multiportal 
VATS operations were formed.  
 
Results: The median age of the included patients was 64 years (18-79 years). Most patients 
were operated by multiportal VATS (87), of which 28 operations had to be converted to an 
open operation. The second most frequent operation was uniportal VATS (40), with a total of 
8 conversions needed. There was no statistical difference in the operation's respective 
conversion ratios (p=0.283). When comparing non-converted uniportal VATS and multiportal 
VATS with open thoracotomies there was no statistically significant difference between gender 
distribution(p=0.287), age (p=0.569), operation durations (p=0.093) or postoperative recovery 
times (p=0.086). The drainage duration was significantly longer in open thoracotomies (6 days) 
compared to the two minimally invasive operations (p=0.016). There was no difference 
between uniportal VATS (5 days) and multiportal VATS (5 days) with respect to drainage 
duration.  
 
Conclusion: This study shows that minimally invasive operation techniques, namely 
multiportal and uniportal VATS, are in many cases better suited surgeries for the treatment of 
lung cancer than an open thoracotomy. This is in concordance with the findings of other recent 
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studies and reflected in multiportal VATS being the gold standard of lung cancer treatment. 
However, there is no clear superiority of uniportal VATS over multiportal VATS to be 
observed, despite it`s even less invasive nature. On the other hand, the results also show no 
drawbacks between the two techniques, suggesting an equivalent clinical value of uniportal 
VATS in the treatment of lung cancer.  
 
 9. CROATIAN SUMMARY
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Naslov: UNIPORTALNI VATS U LIJEČENJU KARCINOMA PLUĆA U KLINIČKOM 
BOLNIČKOM CENTRU SPLIT 
 
Ciljevi: Cilj ovog rada bio je utvrditi trajanje operacije, trajanje drenaže prsnog koša i trajanje 
poslijeoperacijske hospitalizacije bolesnika s karcinomom pluća koji su podvrgnuti 
uniportalnom VATS-u, multiportalnom VATS-u i torakotomijskim postupcima  u Kliničkom 
bolničkom centru Split, u promatranom razdoblju. Nadalje,  koristeći utvrđene parametre, 
studija je uspoređivala tri operacijske tehnike u smislu moguće superiornosti ili inferiornosti 
među njima. 
 
Ispitanici i metode: Od siječnja 2016. do prosinca 2018. u retrospektivnu studiju uključeno je 
150 bolesnika (94 muškarca i 56 žena) koji su na kirurškom odjelu Kliničke bolnice Split 
podvrgnuti operaciji liječenja karcinoma pluća. Prema vrsti operacije kojoj su podvrgnuti, 
ispitanici su podijeljeni u tri glavne skupine: ispitanici liječeni multiportalnim VATS - om (N 
= 59), uniportalnim VATS - om (N = 32) i otvorenom torakotomijom (N = 23). Te skupine 
ispitanika uspoređene su s obzirom na trajanje operacije, trajanje drenaže prsnog koša i duljinu 
postoperativnog boravka u bolnici. Osim toga, formirane su dvije podskupine za konvertirane 
uniportalne i multiportalne VATS zahvate. 
 
Rezultati: Medijan dobi uključenih ispitanika je 64 godine (18-79 godina). Većina ispitanika 
operirana je multiportalnim VATS-om (87), od čega je 28 operacija konvertirano u otvorenu 
operaciju. Druga najčešća operacija bila je uniportalni VATS (40), s ukupno 8 potrebnih 
konverzija. Nije dokazana statistički značajna razlika u stopi konverzije u otvorenu 
torakotomiju između dvije vrste VATS zahvata (p = 0,283). Pri usporedbi nekonvertiranih 
uniportalnih VATS i multiportalnih VATS zahvata s otvorenim torakotomijama nije bilo 
statistički značajne razlike između spolne raspodjele (p = 0,287), dobi (p = 0,569), trajanja 
operacije (p = 0,093) ili duljine poslijeoperacijske hospitlizacije (p = 0,086). Trajanje drenaže 
bilo je značajno duže u ispitanika s otvorenim torakotomijama (6 dana), u usporedbi s oba tipa  
minimalno invazivnih operacija (p = 0,016). Nije bilo razlike između uniportalnog VATS-a (5 
dana) i multiportalnog VATS-a (5 dana) u odnosu na trajanje drenaže prsnog koša. 
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Zaključci: Ova studija pokazuje da su minimalno invazivne operacijske tehnike, odnosno 
multiportalni i uniportalni VATS, bolji izbor od otvorene torakotomije  u kirurškom liječenju 
karcinoma pluća. To je u skladu s nalazima drugih nedavnih studija koje naglašavaju vrijednost 
tehnike multiportalnog VATS-a kao zlatnog standarda u liječenju karcinoma pluća. Međutim, 
ne postoji jasna superiornost uniportalnog VATS-a nad multiportalnim, iako je riječ još manje 
invazivnoj tehnici. S druge strane, rezultati također ne ukazuju niti nedostatke pojedine od ove 
dvije tehnike, što upućuje na ekvivalentnu kliničku vrijednost uniportalnog VATS-a u liječenju 
karcinoma pluća. 
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